Biotechnology ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting June 6, 2022
Biotechnology SHAREHOLDER ALERT: Weiss Law Reminds POLY, TREC, BHVN, and SWCH Shareholders About Its Ongoing Investigations June 6, 2022
Biotechnology GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease June 6, 2022
Biotechnology Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting June 6, 2022
Biotechnology Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO June 5, 2022
Biotechnology Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oscar Health, Axsome, Humbl, and Okta and Encourages Investors to Contact the Firm June 3, 2022
Biotechnology The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FHS, OSCR and AXSM June 3, 2022
Search
Biotechnology
